Barclays
XENE icon

Barclays’s Xenon Pharmaceuticals XENE Stock Holding History

Barclays’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Sell
20,046
-218,163
-92% -$12.1M ﹤0.01% 2682
2026
Q1 		$13.9M Sell
238,209
-362,755
-60% -$16.7M ﹤0.01% 1274
2025
Q4 		$26.9M Buy
600,964
+489,664
+440% +$20.6M 0.01% 1077
2025
Q3 		$4.47M Sell
111,300
-41,470
-27% -$1.46M ﹤0.01% 2294
2025
Q2 		$4.78M Buy
152,770
+133,500
+693% +$4.35M ﹤0.01% 2174
2025
Q1 		$647K Buy
19,270
+1,143
+6% +$43.4K ﹤0.01% 3368
2024
Q4 		$711K Buy
18,127
+3,134
+21% +$130K ﹤0.01% 3605
2024
Q3 		$590K Buy
14,993
+13,903
+1,276% +$561K ﹤0.01% 3678
2024
Q2 		$42.5K Sell
1,090
-11,464
-91% -$458K ﹤0.01% 4265
2024
Q1 		$540K Sell
12,554
-99,436
-89% -$4.57M ﹤0.01% 3539
2023
Q4 		$5.16M Buy
111,990
+102,469
+1,076% +$3.62M ﹤0.01% 2063
2023
Q3 		$325K Buy
9,521
+342
+4% +$12.8K ﹤0.01% 3051
2023
Q2 		$353K Buy
9,179
+9,079
+9,079% +$361K ﹤0.01% 2955
2023
Q1 		$3.58K Buy
+100
New +$3.69K ﹤0.01% 4857
2022
Q2 		– Sell
-191
Closed -$6K – 5297
2022
Q1 		$6K Buy
+191
New +$5.72K ﹤0.01% 4687
2021
Q3 		– Sell
-40
Closed -$1K – 5053
2021
Q2 		$1K Sell
40
-142
-78% -$2.62K ﹤0.01% 4843
2021
Q1 		$3K Buy
182
+96
+112% +$1.63K ﹤0.01% 4540
2020
Q4 		$1K Buy
+86
New +$1.01K ﹤0.01% 4834
2020
Q1 		– Sell
-163
Closed -$2K – 6500
2019
Q4 		$2K Sell
163
-217
-57% -$2.28K ﹤0.01% 6254
2019
Q3 		$3K Buy
+380
New +$3.59K ﹤0.01% 6515
2019
Q2 		– Sell
-2
Closed – – 7326
2019
Q1 		$0 Sell
2
-3,725
-100% -$31.6K ﹤0.01% 7370
2018
Q4 		$24K Buy
+3,727
New +$33.1K ﹤0.01% 5821

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Barclays's XENE Position: Q2 2026 in Review

Barclays reduced its Xenon Pharmaceuticals (XENE) stake by 92% in Q2 2026, selling an estimated $12.1M and leaving 20,046 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2682.

Barclays first reported a position in XENE in Q4 2018 and has held it in 22 quarters since. The position peaked at $26.9M in Q4 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Barclays held 20,046 shares of Xenon Pharmaceuticals worth $1.21M as of Q2 2026.
  • Barclays sold 218,163 Xenon Pharmaceuticals shares in Q2 2026, an estimated $12.1M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2682 holding.
  • Barclays first reported a position in Xenon Pharmaceuticals in Q4 2018 and has held it in 22 quarters since.
  • Barclays's Xenon Pharmaceuticals position peaked at $26.9M in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.